NZ737739B2 - Method for identifying subjects with aggressive melanoma skin cancer at diagnosis - Google Patents
Method for identifying subjects with aggressive melanoma skin cancer at diagnosisInfo
- Publication number
- NZ737739B2 NZ737739B2 NZ737739A NZ73773916A NZ737739B2 NZ 737739 B2 NZ737739 B2 NZ 737739B2 NZ 737739 A NZ737739 A NZ 737739A NZ 73773916 A NZ73773916 A NZ 73773916A NZ 737739 B2 NZ737739 B2 NZ 737739B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- subject
- determining
- diagnosis
- sample
- methylated
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 12
- 201000001441 melanoma Diseases 0.000 title claims abstract 6
- 238000003745 diagnosis Methods 0.000 title claims abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000030381 cutaneous melanoma Diseases 0.000 title 1
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 claims abstract 5
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims abstract 5
- 238000010837 poor prognosis Methods 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 230000011987 methylation Effects 0.000 claims 3
- 238000007069 methylation reaction Methods 0.000 claims 3
- 238000003752 polymerase chain reaction Methods 0.000 claims 2
- 206010027145 Melanocytic naevus Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 206010050283 Tumour ulceration Diseases 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Abstract
The invention is in the field of molecular biology and medical diagnosis. It provides means and methods for determining the prognosis and disease outcome of a subject having a melanoma. More in particular, it provides a method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample from the subject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor prognosis.
Claims (7)
1. Method for determining whether a subject having a melanoma has a poor prognosis, the method comprising the step of determining in a sample previously 5 obtained from the subject whether the LY75 promoter is methylated and if the LY75 promoter is methylated, classifying the subject as having a poor prognosis.
2. Method according to claim 1 wherein the sample is obtained from the skin of the subject or from a melanoma or a nevus.
3. Method according to claim 1 or 2 wherein the sample is obtained from a biopsy 10 taken from the subject.
4. Method according to any one of claims 1 – 3 wherein an additional step is performed selected from the group consisting of determining tumor ulceration, determining metastatic disease at diagnosis, disease stage, and Breslow thickness of the melanoma. 15
5. Method according to any one of claims 1 – 4 wherein the step of determining in a sample from the subject whether the LY75 promoter is methylated is performed by multiplex methylation-specific polymerase chain reaction analysis.
6. Method according to claim 5 wherein the multiplex methylation-specific polymerase chain reaction is a nested multiplex methylation-specific polymerase 20 chain reaction.
7. The method according to any one of claims 1-6 substantially as herein described and with reference to any example thereof and with or without reference to the figures. PCT7EP
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15169951 | 2015-05-29 | ||
| PCT/EP2016/061913 WO2016193117A1 (en) | 2015-05-29 | 2016-05-26 | Method for identifying subjects with aggressive melanoma skin cancer at diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ737739A NZ737739A (en) | 2024-04-26 |
| NZ737739B2 true NZ737739B2 (en) | 2024-07-30 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yaman Agaoglu et al. | Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer | |
| US10907214B2 (en) | Methods for predicting drug responsiveness in cancer patients | |
| WO2013148147A8 (en) | Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms | |
| HK1254531A1 (en) | Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers | |
| WO2008154098A3 (en) | Reagents and methods for mirna expression analysis and identification of cancer biomarkers | |
| AU2019301959B2 (en) | DNA methylation markers for noninvasive detection of cancer and uses thereof | |
| Pesson et al. | A gene expression and pre-mRNA splicing signature that marks the adenoma-adenocarcinoma progression in colorectal cancer | |
| EA202092900A3 (en) | PLASMA DNA MUTATION ANALYSIS FOR CANCER DETECTION | |
| WO2011103236A3 (en) | Personalized tumor biomarkers | |
| WO2017143296A3 (en) | Prostate cancer aggressiveness biomarkers | |
| WO2007143037A3 (en) | Gene methylation in cancer diagnosis | |
| Thusgaard et al. | Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review | |
| Pennathur et al. | Gene expression profiles in esophageal adenocarcinoma predict survival after resection | |
| WO2018097614A3 (en) | Method for predicting effectiveness of chemotherapy in breast cancer patients | |
| WO2019191429A3 (en) | Identification of epigenetic alterations in dna isolated from exosomes | |
| Truong et al. | BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population | |
| PH12022552766A1 (en) | Method for early detection, prediction of treatment response and prognosis of colorectal cancer | |
| WO2016034715A3 (en) | Method for predicting the development of colorectal cancer | |
| Wojdacz et al. | Identification and characterization of locus-specific methylation patterns within novel loci undergoing hypermethylation during breast cancer pathogenesis | |
| Gonzalez-Kozlova | Molecular profiling of liquid biopsies for precision oncology | |
| MX2022007434A (en) | Methods for detecting colorectal cancer. | |
| WO2008104985A3 (en) | Methods for distingushing between lung squamous carcinoma and other non smallcell lung cancers | |
| WO2012135091A3 (en) | Serum-based mirna microarray and its use in diagnosis and treatment of barrett's esophagus (be) and esophageal adenocarcinoma (eac) | |
| Meder et al. | Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases | |
| NZ737739B2 (en) | Method for identifying subjects with aggressive melanoma skin cancer at diagnosis |